Amgen Waged Lawfare To Overcharge For Drug, Suit Claims

By Corey Rothauser · August 7, 2024, 7:48 PM EDT

Maryland-based independent licensees of the Blue Cross Blue Shield Association claim pharmaceutical giant Amgen Inc. and its subsidiaries have engaged in unlawful monopolistic practices that have inflated the cost of the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Carefirst of Maryland, Inc. et al v. Amgen, Inc. et al

Case Number

Court

Virginia Eastern

Nature of Suit

Anti-Trust

Date Filed

August 06, 2024

Recent Articles By Corey

June 18, 2024
Company, States Battle In Court Over At-Home Rape Kits
January 19, 2024
Kenvue Execs, J&J Face 2nd Investor Action Over FDA Probe
December 21, 2023
Camp Lejeune Victims Must Reveal Personal Info, Judge Says
December 20, 2023
Landfill Workers Say Co. Fired Them For Safety Complaints
August 10, 2023
Cancer Drug's Delay Amounts To Extortion, Clinic Says